|

Endocardial Mapping With the CoreMap EP Mapping System

RECRUITINGN/ASponsored by CoreMap Inc.
Actively Recruiting
PhaseN/A
SponsorCoreMap Inc.
Started2024-07-25
Est. completion2026-12-31
Eligibility
Age18 Years – 80 Years
Healthy vol.Accepted
Locations2 sites

Summary

This is a global, multi-site, prospective, feasibility study.

Eligibility

Age: 18 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria:

1. Subject has persistent or long-standing persistent AF, at the discretion of the investigator (Phase 1 \& 2)
2. Subject has PerAF with no history of prior AF ablation therapy (Phase 3)
3. Subject is 18 to 80 years of age
4. Subject has presence of AF-related symptoms and is scheduled for clinically indicated standard of care AF ablation to manage PerAF (Phase 2 or 3) or long-standing PerAF (Phase 2)
5. Subject is able to provide written informed consent
6. Subject is able and willing to complete all study procedures

Exclusion Criteria:

1. Any of the following within three months of enrollment:

   1. Myocardial infarction (MI)
   2. Any surgical or percutaneous cardiac procedure including coronary intervention and cardiac ablation
   3. Confirmed thrombus on imaging
2. Any of the following within six months of enrollment:

   1. Cardiac surgery including coronary artery bypass grafting, ventriculotomy, atriotomy
   2. Thromboembolic event (stroke)
3. Any of the following cardiac conditions:

   1. New York Heart Association (NYHA) IV
   2. Left ventricular ejection fraction (LVEF) \< 30%
   3. Left atrial diameter \>55mm (anterioposterior) (Phase 3)
   4. Carotid stenting or endarterectomy
   5. Atrial or ventricular septal closure or left atrial appendage closure
   6. Implanted permanent pacemaker, biventricular pacemaker, or any type of implantable cardiac defibrillator; loop recorders are permitted.
   7. Presence of intramural thrombus, tumor (including atrial myxoma), or other abnormality that precludes vascular access, catheter introduction, or manipulation
   8. Unstable angina
   9. Prior mitral or tricuspid valve surgery, repair, prosthetic or mechanical valve
   10. Moderate to severe mitral valve stenosis or other severe valvular disease
   11. Any blood clotting or bleeding abnormalities
4. Contraindication to systemic anticoagulation
5. AF secondary to electrolyte imbalance, acute alcohol intoxication, or reversible or non-cardiac cause
6. Body mass index (BMI) \> 40 kg/m2
7. Severe pulmonary disease, pulmonary hypertension, or any chronic respiratory condition
8. Renal failure requiring dialysis or transplant
9. Acute illness, active systemic infection, or sepsis
10. Active drug or alcohol dependency
11. Hypertrophic cardiomyopathy or cardiac amyloidosis
12. Cor pulmonale
13. Any contra-indication that may extend procedure time, at the discretion of the operator
14. Any woman known to be pregnant or breastfeeding, or any woman of childbearing potential who is not on a reliable form of birth regulation method or abstinence
15. Subject considered part of vulnerable population
16. Life expectancy less than one year
17. Employee of the study site or Sponsor
18. Subjects who are currently enrolled in another study that would directly interfere with this study

Conditions2

Heart DiseasePersistent Atrial Fibrillation

Locations2 sites

Florida

1 site
NCH Downtown Baker Hospital
Naples, Florida, 34102

Vermont

1 site
University of Vermont Medical Center
Burlington, Vermont, 05401

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.